Infasurf
Phase 2Small molecule
Infasurf is one of 16 small molecule programs targeting Chronic Lung Disease. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Chronic Lung Disease
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Pulmicort
SSalix
Approved
Aldactone
PfizerPhase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Inomax
MMallinckrodt
Phase 3
Qvar
Chiesi Farmaceutici S.p.A.Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Spiriva
Boehringer IngelheimPhase 3
Viagra
VViatris Specialty LLC
Phase 3
Ino
UUniversity of Colorado, Denver
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Lung Disease1 trial
Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.
Unknown status·—·Phase 2·NCT01268215·45 enrolled
Prophylaxis1 trial
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
Completed·—·N/A·NCT00208039·89 enrolled
Nitric Oxide1 trial
Pre-Term1 trial
Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation
Completed·—·N/A·NCT00165074·11 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Infasurf. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRoberta Ballard